Sodium-glucose Transport 2 Inhibitors (SGLT2i) in HFrEF Patients

• Status: Recruiting
• Trial end date: 2024-03-30
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to assess the efficacy, safety and cardiovascular outcomes of Sodium-glucose transport protein 2 inhibitors (SGLT2i) therapy in patients with heart failure reduced ejection fraction ( HFrEF) with and without diabetes mellitus and is to evaluate short-term effect of these drugs using the cardiac biomarkers Neopterin.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Damanhour University
• Treatments: Dapagliflozin; Empagliflozin

Criteria

Inclusion criteria:

• Patients with HFrEF, on optimal medical therapy according to European Society of Cardiology guidelines,

• an age of at least 18 years,

• an ejection fraction of 40% or less, with New York Heart Association (NYHA) class II - IV symptoms will be eligible for the study.

Exclusion criteria:

• Recent treatment with or unacceptable side effects associated with an SGLT2i

• Type-I diabetes mellitus,

• Symptoms of hypotension or a systolic blood pressure of less than 95 mm Hg,

• Severe CKD and an estimated glomerular filtration rate (eGFR) below 30 ml per minute per 1.73 m2 of body-surface area or rapidly declining renal function

• Inability to give informed consent